99 related articles for article (PubMed ID: 23158643)
1. Keratosis pilaris-like eruption observed during the experimental PLX 4032 studies.
van der Kooi K; Glass LF; Messina JL; Trimble JS
J Am Acad Dermatol; 2012 Dec; 67(6):e286-7. PubMed ID: 23158643
[No Abstract] [Full Text] [Related]
2. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
[No Abstract] [Full Text] [Related]
3. Eosinophilic Infiltrates in Vemurafenib-Associated Verrucous Keratoses.
Longhurst WD; Honda K; Koon HB; Gerstenblith MR
Am J Dermatopathol; 2016 Oct; 38(10):766-8. PubMed ID: 27533075
[No Abstract] [Full Text] [Related]
4. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae.
Ko CJ; McNiff JM; Iftner A; Iftner T; Choi JN
J Am Acad Dermatol; 2013 Aug; 69(2):e95-6. PubMed ID: 23866896
[No Abstract] [Full Text] [Related]
7. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.
Huang V; Hepper D; Anadkat M; Cornelius L
Arch Dermatol; 2012 May; 148(5):628-33. PubMed ID: 22431713
[TBL] [Abstract][Full Text] [Related]
8. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
[No Abstract] [Full Text] [Related]
9. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.
Boyd KP; Vincent B; Andea A; Conry RM; Hughey LC
J Am Acad Dermatol; 2012 Dec; 67(6):1375-9. PubMed ID: 22940405
[TBL] [Abstract][Full Text] [Related]
10. Lupus erythematosus-like skin eruption after vemurafenib therapy.
Reinholz M; Berking C; Hermans C; Ruzicka T; Braun-Falco M
J Am Acad Dermatol; 2014 Oct; 71(4):e159-60. PubMed ID: 25219748
[No Abstract] [Full Text] [Related]
11. Sarcoidosis associated with vemurafenib.
Adam A; Thomas L; Bories N; Zaharia D; Balme B; Freymond N; Dalle S
Br J Dermatol; 2013 Jul; 169(1):206-8. PubMed ID: 23834124
[No Abstract] [Full Text] [Related]
12. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption.
Gupta M; Huang V; Linette G; Cornelius L
Arch Dermatol; 2012 Aug; 148(8):966-8. PubMed ID: 22911209
[No Abstract] [Full Text] [Related]
13. Pyogenic granuloma as a cutaneous adverse effect of vemurafenib.
Sammut SJ; Tomson N; Corrie P
N Engl J Med; 2014 Sep; 371(13):1265-7. PubMed ID: 25251629
[No Abstract] [Full Text] [Related]
14. Eruptive milia secondary to vemurafenib.
Sambrano BL; Riddel CE; Chon SY
J Am Acad Dermatol; 2013 Nov; 69(5):e258-e260. PubMed ID: 24124854
[No Abstract] [Full Text] [Related]
15. Vemurafenib sensitivity skin reaction after ipilimumab.
Harding JJ; Pulitzer M; Chapman PB
N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
[No Abstract] [Full Text] [Related]
16. Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer.
Kenner JR; Sperling LC; Waselenko J; Dawson N; Sau P; Moul JW
J Urol; 1997 Dec; 158(6):2245-6. PubMed ID: 9366363
[No Abstract] [Full Text] [Related]
17. Vemurafenib-induced panniculitis.
Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
[No Abstract] [Full Text] [Related]
18. How cutaneous eruptions help to understand the mode of action of kinase inhibitors.
Dummer R; Tsao H; Robert C
Br J Dermatol; 2012 Nov; 167(5):965-7. PubMed ID: 23106351
[No Abstract] [Full Text] [Related]
19. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
20. Eccrine squamous syringometaplasia associated with vemurafenib therapy.
Story SG; Beschloss JK; Dolan CK; Thomas BC
J Am Acad Dermatol; 2012 Nov; 67(5):e208-10. PubMed ID: 23062917
[No Abstract] [Full Text] [Related]
[Next] [New Search]
